News about Market

Novo Nordisk Implements Global Hiring Freeze Amid Wegovy Pressure

Novo Nordisk, the pharmaceutical major behind the blockbuster obesity drug Wegovy, has imposed a global hiring freeze, halting recruitment for all non-critical positions. The move reflects intensifying pressure from increasing competition and market volatility.

Market | 21/08/2025 | By Darshana

India's Drugs and Pharma Exports Rise 14 Percent in July

India’s exports of drugs and pharmaceuticals rose sharply in July 2025, reaching USD 2,662.24 million, up from USD 2,334.14 million in the same month last year , according to the latest trade data released by the Department of Commerce.

Market | 20/08/2025 | By Dineshwori |  113

Pharmaceutical Inspection Machines Market to Reach USD 1.66 Billion by 2030: Report

The pharmaceutical inspection machines market is undergoing rapid transformation, driven by digital transformation, regulatory pressures, and increased demand for production agility.

Market | 19/08/2025 | By Dineshwori

Accord BioPharma Launches IMULDOSA Prefilled Syringes at Lowest WAC Price

Accord BioPharma has announced the commercial launch of IMULDOSA (ustekinumab-srlf), a biosimilar to STELARA (ustekinumab).

Market | 19/08/2025 | By Dineshwori

Glenmark Eyes 10-15 percent India Growth by Prioritising High-Margin Branded Products

Glenmark Pharmaceuticals is targeting a compounded annual growth rate (CAGR) of 10–15 % for its India business over the next two to three years by shifting its focus up the value chain and expanding its portfolio of high-margin branded products.

Market | 19/08/2025 | By Darshana

Aurobindo Pharma's China Manufacturing Plant to Reach EBITDA Break-Even by Q3 FY26

The facility began operations in late November 2024 and is currently ramping up production. With an initial annual capacity exceeding two billion units, it has already started production and invoicing between Q4 FY25 and Q1 FY26. The company has invested approximately USD 145 million in setting up the plant.

Market | 18/08/2025 | By Darshana

Manufacturing and Market Risks Mount as Scorpion Capital Bets Against Soleno's PWS Therapy

The hedge fund cited issues with Vykat XR, Soleno’s recently approved treatment for Prader-Willi syndrome, citing risks of fluid accumulation in the lungs and potential heart failure. Scorpion also suggested that the drug could eventually be withdrawn from the market.

Market | 17/08/2025 | By Darshana |  110

Navamedic Sees Over 48% YoY Growth in Antibiotics Sales Boosted by Tender Wins

During the second quarter, Navamedic’s Hospital business delivered strong growth, driven primarily by Nordic tender wins in its antibiotics portfolio.

Market | 14/08/2025 | By Dineshwori

US Antibody Drug Conjugates Market projected to Surpass USD 11 billion by 2034

The growth of US antibody drug conjugates (ADCs) market is driven by the rising investments in ADC research and development for discovering and developing novel and targeted cancer therapies.

Market | 13/08/2025 | By Dineshwori

Senores Pharmaceuticals to Acquire Two ANDAs from Teva in USD 120 Million Market Opportunity

Senores Pharmaceuticals (SPL), through its wholly-owned US subsidiary Senores Pharmaceuticals, USA (SPI), has signed an agreement to acquire two USFDA-approved Abbreviated New Drug Applications (ANDAs) from Teva Pharmaceuticals USA.

Market | 13/08/2025 | By Darshana